Craif, Inc. Craif participates in the femtech community “Value Add Femtech(TM) Community” founded by NTT C ommunications

Craif Inc.
Craif Participates in Femtech Community “Value Add Femtech(TM) Community” Founded by NTT Communications

Craif Inc. (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose,
hereinafter Craif) is a business co-creation company founded by NTT Communications Corporation (Headquarters: Chiyoda-ku, Tokyo, President: Toru Maruoka, hereinafter NTT Com). We will participate in the community “Value Add Femtech(TM) Community” (hereinafter referred to as “this community”).
Outline of “Value Add Femtech(TM) Community”
This community utilizes NTT Com’s platform for the healthcare industry, “Smart Data Platform for Healthcare” (hereafter, SDPF for healthcare), to link data between various femtech businesses and create new opportunities for utilization. It is a community among businesses that develops and provides high-value-added products and services and aims to improve the quality of life (QOL) of women who are the end users.
Background of participation in this community
In February 2022, Craif began providing miSignal(R), a cancer risk test, which covers seven types of cancer, including breast cancer and ovarian cancer. Although treatment results for breast and ovarian cancer have improved due to recent medical advances, if cancer is found after it has progressed, painful treatment is required, leading to a decline in the quality of life of cancer patients. There are many cases. Craif will contribute to improving the QOL of women by promoting early detection methods for female cancer through the use of miSignal(R)︎.
Leading company of “Value Add Femtech(TM) Community”
[Imaged41883-80-972de1d3cd298eb5decd-0.png&s3=41883-80-92b8a0c67a7575a8a327495bbc5a0ae1-1000x451.png
NTT Communications Corporation
About Craif
Craif is a Nagoya University-launched venture company founded in May 2018. By comprehensively capturing microRNAs from urine using materials that Japan is proud of, combining them with AI (artificial intelligence) and applying them to medical care, we will be able to detect diseases at an early stage and provide personalized medicine, mainly in the area of ​​cancer. We are working on next-generation inspection development to realize Through collaboration with the world’s leading companies and organizations in the medical and healthcare fields, we will promote our vision of “realizing a society where people can live out their natural lives.” For more information, please visit https://craif.com/.
Details about this release:
https://prtimes.jp/main/html/rd/p/000000080.000041883.html

MAIL:cr@prtimes.co.jp

rehow

%d bloggers like this: